Stocks and Investing Stocks and Investing
Tue, July 11, 2023

Jeffrey Hung Maintained (ACAD) at Hold with Increased Target to $21 on, Jul 11th, 2023


Published on 2024-10-28 04:43:36 - WOPRAI, Jeffrey Hung
  Print publication without navigation


Jeffrey Hung of Morgan Stanley, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $20 to $21 on, Jul 11th, 2023.

Jeffrey has made no other calls on ACAD in the last 4 months.



There are 10 other peers that have a rating on ACAD. Out of the 10 peers that are also analyzing ACAD, 4 agree with Jeffrey's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Uy Ear of "Mizuho" Reiterated at Hold and Held Target at $20 on, Wednesday, June 14th, 2023
  • Tazeen Ahmad of "B of A Securities" Maintained at Hold with Increased Target to $26 on, Monday, May 22nd, 2023
  • Neena Bitritto-Garg of "Citigroup" Maintained at Hold with Increased Target to $22 on, Tuesday, May 9th, 2023
  • Julio Romero of "JP Morgan" Maintained at Hold with Increased Target to $21 on, Monday, March 20th, 2023


These are the ratings of the 6 analyists that currently disagree with Jeffrey


  • Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $28 on, Wednesday, June 14th, 2023
  • Jason Butler of "JMP Securities" Maintained at Buy with Increased Target to $31 on, Wednesday, June 14th, 2023
  • Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $27 on, Tuesday, May 9th, 2023
  • Sarah James of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $33 on, Tuesday, May 9th, 2023
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $33 on, Tuesday, March 14th, 2023
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $26 on, Tuesday, March 14th, 2023
Contributing Sources